PRFX | PainReform Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4410 - 0.4850
52 Week Range	0.4320 - 20.16
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	46,601
Average Volume	495,296
Shares Outstanding	2,226,450
Market Cap	1,027,729
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2020-09-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-36.84
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	Israel
Website	PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PRFX's peers: BFRI, CPIX, CRDL, EVOK, FLGC, QLI, RGC, PROC, JUPW, UPC, VRTHF, EGRX, SGBI, CLVR, INCR, LOWLF, GRCU, CNNA, RMRK, GXXY, INQD, PTPI, RDHL, SXTC, TXMD

*Chart delayed

Analyzing fundamentals for PRFX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PRFX Fundamentals page.

Watching at PRFX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PRFX Technicals page.